0001979666-26-000004.txt : 20260123
0001979666-26-000004.hdr.sgml : 20260123
20260123200244
ACCESSION NUMBER: 0001979666-26-000004
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20260123
DATE AS OF CHANGE: 20260123
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 26558227
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Porter Fred
CENTRAL INDEX KEY: 0001979666
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O TAYSHA GENE THERAPIES, INC.
STREET 2: 3000 PEGASUS PARK DRIVE, SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
144
1
primary_doc.xml
144
0001979666
XXXXXXXX
LIVE
0001806310
TAYSHA GENE THERAPIES, INC.
001-39536
3000 PEGASUS PARK DRIVE
SUITE 1430
DALLAS
TX
75247
214-612-0000
Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
Common Stock
Maxim Group LLC
300 Park Avenue, 16th Floor
New York
NY
10022
54916
279522.44
273919373
01/23/2026
Nasdaq
Common Stock
01/23/2026
RSU Award
Issuer
N
54916
01/23/2026
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
Y
The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
01/23/2026
/s/ Frederick Porter